Physician profile
Kamran Matin
NPI 1225074982
$18,237.09
in general payments reported to CMS, 2019-2025
53 companies · $3,071 in 2025
The $3,071 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,162 · 2020: $1,309 · 2021: $2,396 · 2022: $2,427 · 2023: $3,458 · 2024: $3,415 · 2025: $3,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,849 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,849.05 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,920.39 | 2019-2025 | |
| Viiv Healthcare Company | $1,569.80 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Astrazeneca Pharmaceuticals LP | $1,501.26 | 2019-2025 | Farxiga, Brilinta, Wainua |
| E.R. Squibb & Sons, L.L.C. | $1,413.80 | 2019-2025 | Camzyos, Eliquis |
| Gilead Sciences, INC. | $1,185.20 | 2021-2025 | Descovy, Yeztugo, Biktarvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $989.36 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $935.83 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $901.97 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $811.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $784.38 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $650.93 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $643.98 | 2019-2022 | |
| Amgen INC. | $551.96 | 2019-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $529.60 | 2023-2025 | Inpefa |
| Janssen Pharmaceuticals, INC | $509.03 | 2019-2023 | Xarelto |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Matin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.